CryoLife (CRY) Revenue Growth Should Begin to Accelerated, PT Raised to $38 at Needham
Tweet Send to a Friend
Needham & Company analyst Matt Matson raised the price target on CryoLife (NYSE: CRY) to $38.00 (from $33.00) after 1Q21 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
